Additionally, CRP ≥0.2 mg/dL was linked to pan-NEN-related deaths (both median not reached; 5-year DSS: 87.7% vs. 98% and 10-year DSS: 78.2% vs. 98%; p = 0.002) However, CRP ≥0.2 mg/dL was not associated with inferior RFS (both median not reached; 5-year RFS: 72.2% vs. 70.4%; p = 0.893) or a significantly increased recurrence rate (25.6% vs. 21.2%; p = 0.343) We therefore hypothesized that recurrence in high-CRP cases might not occur earlier or more often but may be associated with more aggressive behavior of tumor relapse and impaired host-defensive abilities. The gene discussed is CRP; the disease is neoplasm.